- Q1 2024 Seres Therapeutics Inc Earnings Call TranscriptMay 08, 2024$0.7494 (-32.49%)Earnings
- Q4 2023 Seres Therapeutics Inc Earnings Call TranscriptMar 05, 2024$1.06 (-7.02%)Earnings
- Seres Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Q3 2023 Seres Therapeutics Inc Earnings Call TranscriptNov 02, 2023$0.9324 (-35.25%)Earnings
- Seres Therapeutics Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 11, 2023
- Seres Therapeutics Inc at Canaccord Genuity Growth Conference TranscriptAug 09, 2023
- Q2 2023 Seres Therapeutics Inc Earnings Call TranscriptAug 08, 2023$4.29 (-6.94%)Earnings
- Seres Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- Seres Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Q1 2023 Seres Therapeutics Inc Earnings Call TranscriptMay 09, 2023$5.57 (+0.18%)Earnings
- Seres Therapeutics Inc To Discuss SER-109 Approval Call TranscriptApr 27, 2023
- Q4 2022 Seres Therapeutics Inc Earnings Call TranscriptMar 07, 2023$5.4 (-1.64%)Earnings
- Seres Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 12, 2023
- Seres Therapeutics Inc To Discuss Ser-109 Commercial Strategy Call TranscriptDec 08, 2022
- Q3 2022 Seres Therapeutics Inc Earnings Call TranscriptNov 02, 2022$8.19 (-9.50%)Earnings
- Q2 2022 Seres Therapeutics Inc Earnings Call TranscriptAug 03, 2022$4.45 (+8.54%)Earnings
- Seres Therapeutics Inc To Discuss 109 ECOSPOR IV Study Results Call TranscriptJun 07, 2022
- Q1 2022 Seres Therapeutics Inc Earnings Call TranscriptMay 04, 2022$4.72 (-2.48%)Earnings
- Q4 2021 Seres Therapeutics Inc Earnings Call TranscriptMar 01, 2022$7.4 (-7.56%)Earnings
- Seres Therapeutics Inc To Highlight Opportunities For Microbiome Therapeutics In Infection Protection Call TranscriptJan 31, 2022
- Seres Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Q3 2021 Seres Therapeutics Inc Earnings Call TranscriptNov 10, 2021$8.27 (+20.38%)Earnings
- Q2 2021 Seres Therapeutics Inc Earnings Call TranscriptAug 03, 2021$6.96 (-1.00%)Earnings
- Seres Therapeutics Inc To Discuss Topline Results From The Phase 2b ECO-RESET Study Evaluating SER-287 In Patients With Mild-To-Moderate Ulcerative Colitis Call TranscriptJul 22, 2021
- Seres Therapeutics Inc SER-109 Co-Commercialization License Agreement Call TranscriptJul 01, 2021
- Seres Therapeutics Inc SER-287 Clinical Data Update Call TranscriptJun 21, 2021
- Seres Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 08, 2021
- Q1 2021 Seres Therapeutics Inc Earnings Call TranscriptMay 04, 2021$21.48 (+5.55%)Earnings
- Q4 2020 Seres Therapeutics Inc Earnings Call TranscriptMar 02, 2021$19.62 (-4.85%)Earnings
- Seres Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Q3 2020 Seres Therapeutics Inc Earnings Call TranscriptNov 09, 2020$33.24 (-3.90%)Earnings
- Seres Therapeutics, Inc. - Special Call TranscriptAug 10, 2020
- Seres Therapeutics Inc Annual Shareholders Meeting TranscriptJun 18, 2020
- Seres Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 09, 2020
- Seres Therapeutics, Inc. - Special Call TranscriptMay 27, 2020
- Q1 2020 Seres Therapeutics Inc Earnings Call TranscriptMay 07, 2020$4.27 (+12.37%)Earnings
- Q4 2019 Seres Therapeutics Inc Earnings Call TranscriptMar 02, 2020$3.23 (+2.87%)Earnings
- Q3 2019 Seres Therapeutics Inc Earnings Call TranscriptNov 05, 2019$4.06 (+6.84%)Earnings
- Q2 2019 Seres Therapeutics Inc Earnings Call TranscriptAug 06, 2019$2.29 (-6.15%)Earnings
- Q1 2019 Seres Therapeutics Inc Earnings Call TranscriptMay 02, 2019$5.35 (-12.44%)Earnings
- Q4 2018 Seres Therapeutics Inc Earnings Call TranscriptMar 06, 2019$6.12 (-3.62%)Earnings
Seres Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Great. Good afternoon, everybody. Thank you for joining us. I'm Terence Flynn, the biopharma analyst at Goldman Sachs, and we're very pleased to have Seres Therapeutics with us. Today from the company we have Eric Shaff, President and CEO; Matt Henn, Chief Scientific Officer; and Lisa von Moltke, who's Chief Medical Officer. Thank you all for joining us. Really appreciate your time today.
Maybe just to get started, was wondering if you could just give a brief overview of the company and the current development programs for those of us that aren't as familiar with the company.
Sure, Terence, and thank you, again, for having us here today. Thanks to Goldman for having us here to talk about Seres and what we think is going to be an incredibly important year for the company and for the microbiome space.
Before I start, I'll just note, we will be making forward-looking statements. So as usual, please refer to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)